TargetBeta
GABRG2
gamma-aminobutyric acid type A receptor subunit gamma2 · Gamma-aminobutyric acid type A receptor subunits
5 programs in company-led studies act on GABRG2, from 5 companies: 1 in phase 3, 4 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Midazolamrule | Pfizer | phase 4 | 966 running | GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG3, GABRP, GABRQ | ChEMBL |
| ciprofolrule | Haisco Pharmaceutical Group | phase 4 | 362 running | GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG3, GABRP, GABRQ | ChEMBL |
| Alprazolamrule | Viatris | phase 4 | 352 running | GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG3, GABRP, GABRQ | ChEMBL |
| brexanolonerule | Supernus Pharmaceuticals | phase 4 | 141 running | GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG3, GABRP, GABRQ | ChEMBL |
| Diazepamrule | Acorda Therapeutics | phase 3 | 90 running | GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG3, GABRP, GABRQ | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Epilepsy, 3 programs
- Seizures, 2 programs
- Anxiety Disorders, 1 program
- Arrhythmias, Cardiac, 1 program
- Asthma, 1 program
- Depression, Postpartum, 1 program
- Diabetes Mellitus, Type 2, 1 program
- Drug Resistant Epilepsy, 1 program
- Essential Tremor, 1 program
- HIV Infections, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 25, 2026Midazolam · Pfizer · phase 4 · NCT07859007
- Mar 29, 2027Alprazolam · Viatris · phase 4 · NCT05077904
- Aug 2027brexanolone · Supernus Pharmaceuticals · phase 4 · NCT07822321
- May 2028ciprofol · Haisco Pharmaceutical Group · phase 4 · NCT07510945
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.